All In Biotech

Drug Trial Radar · NCT03281681

A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer

A Phase 1/2, Open Label, Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Oct 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Mar 2021

Primary completion

Mar 2022

Study completion Sep 2022

Sponsor

Lead sponsor
DelMar Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Sep 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, multi-center, Phase 1/2 clinical trial in subjects with recurrent adenocarcinoma of the ovary who have been previously treated with a minimum of two courses of platinum-based chemotherapy, and up to two additional cytotoxic regimens that may also have included platinum (no more than four total lines of prior therapy), with or without bevacizumab, whose cancer has recurred within six months of the most recent platinum-based chemotherapy. All eligible subjects will receive VAL 083 i.v. in a once weekly cycle until disease progression, development of other unacceptable toxicity, death, withdrawal of consent, loss to follow-up, or Sponsor ending the study, whichever occurs first.

Conditions

  • Ovarian Cancer

Interventions

  • VAL-083, DianhydrogalactitolDrug

    VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimate Overall Response RateTime frame: Every 8 weeks from Screening to achievement of either complete response (CR) or partial response (PR) for at least 6 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • Henry Ford Hospital

    Detroit, Michigan

  • Sarah Cannon Research Institute

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.